Literature DB >> 32213021

Discriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study.

Brjánn Ljótsson1,2, Michael Jones3, Nicholas J Talley4, Lars Kjellström5, Lars Agréus6, Anna Andreasson3,7,8.   

Abstract

BACKGROUND: The Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) is a 13-item measure of IBS symptom severity. The scale has been used in several studies, but its psychometric properties have been insufficiently investigated and population-based data are not available.
OBJECTIVE: The objective of this article is to establish the factor structure and discriminant and convergent validity of the GSRS-IBS.
METHODS: The study was based on a Swedish population sample (the Popcol study), of which 1158 randomly selected participants provided data on the GSRS-IBS. We used confirmatory factor analysis (CFA) and compared total and subscales scores in different groups, including IBS diagnostic status, treatment-seeking behavior, and predominant bowel habits. The GSRS-IBS scores were also correlated with quality of life indexes.
RESULTS: The sample included 164 participants with a confirmed Rome III IBS diagnosis and 994 participants without the disease. The CFA confirmed the subscales with one exception, in which the incomplete bowel-emptying item belonged to the constipation subscale rather than the diarrhea subscale. The GSRS-IBS total score and subscales were associated with diagnostic status, treatment-seeking behavior, and quality of life dimensions. The relevant subscales scores also differed between the diarrhea- and constipation-predominant subtypes of IBS.
CONCLUSION: The GSRS-IBS total score and subscales have high discriminant and convergent validity. The CFA confirmed the overall validity of the subscales but suggest that a sense of incomplete emptying belongs to the constipation rather than the diarrhea symptom cluster. We conclude that the GSRS-IBS is an excellent measure of IBS symptom severity in the general population.

Entities:  

Keywords:  Irritable bowel syndrome; patient-reported outcomes; population study; psychometric evaluation; symptom severity

Mesh:

Year:  2020        PMID: 32213021      PMCID: PMC7184654          DOI: 10.1177/2050640619900577

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  24 in total

1.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

2.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.

Authors:  C Y Francis; J Morris; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

3.  How does exposure therapy work? A comparison between generic and gastrointestinal anxiety-specific mediators in a dismantling study of exposure therapy for irritable bowel syndrome.

Authors:  Hugo Hesser; Erik Hedman-Lagerlöf; Erik Andersson; Perjohan Lindfors; Brjánn Ljótsson
Journal:  J Consult Clin Psychol       Date:  2018-03

4.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

5.  Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials.

Authors:  Perjohan Lindfors; Peter Unge; Patrik Arvidsson; Henry Nyhlin; Einar Björnsson; Hasse Abrahamsson; Magnus Simrén
Journal:  Am J Gastroenterol       Date:  2011-10-04       Impact factor: 10.864

Review 6.  Functional bowel disorders.

Authors:  George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 7.  Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  Alexander C Ford; Eamonn M M Quigley; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

8.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

9.  Altered rectal perception in irritable bowel syndrome is associated with symptom severity.

Authors:  Iris Posserud; Alma Syrous; Lina Lindström; Jan Tack; Hasse Abrahamsson; Magnus Simrén
Journal:  Gastroenterology       Date:  2007-07-25       Impact factor: 22.682

10.  Mechanisms of change in an exposure-based treatment for irritable bowel syndrome.

Authors:  Brjánn Ljótsson; Hugo Hesser; Erik Andersson; Perjohan Lindfors; Timo Hursti; Christian Rück; Nils Lindefors; Gerhard Andersson; Erik Hedman
Journal:  J Consult Clin Psychol       Date:  2013-06-10
View more
  3 in total

1.  Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort.

Authors:  Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton
Journal:  Mov Disord Clin Pract       Date:  2021-01-05

2.  Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth.

Authors:  Cezary Chojnacki; Paulina Konrad; Aleksandra Błońska; Marta Medrek-Socha; Karolina Przybylowska-Sygut; Jan Chojnacki; Tomasz Poplawski
Journal:  Nutrients       Date:  2022-08-06       Impact factor: 6.706

3.  A cross-sectional study of gastrointestinal symptoms, depressive symptoms and trait anxiety in young adults.

Authors:  Fanny Söderquist; Mikaela Syk; David Just; Zorana Kurbalija Novicic; Annica J Rasmusson; Per M Hellström; Mia Ramklint; Janet L Cunningham
Journal:  BMC Psychiatry       Date:  2020-11-11       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.